Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics

被引：42

作者：

Cardama, G. A. ^{[1
]}

Alonso, D. F. ^{[1
,2
]}

Gonzalez, N. ^{[1
]}

Maggio, J. ^{[1
]}

Gomez, D. E. ^{[1
,2
]}

Rolfo, C. ^{[3
,4
]}

Menna, P. L. ^{[1
,2
]}

机构：

[1] Natl Univ Quilmes, Lab Mol Oncol, Buenos Aires, DF, Argentina

[2] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina

[3] Antwerp Univ, Phase Early Clin Trials Unit 1, Oncol Dept, Antwerp Univ Hosp, Antwerp, Belgium

[4] Antwerp Univ, Ctr Oncol Res CORE, Antwerp, Belgium

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2018年 / 124卷

关键词：

Rac1; inhibition; Chemoresistance; Radioresistance; Targeted-therapy; Immune evasion; GROWTH-FACTOR RECEPTOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; TO-MESENCHYMAL TRANSITION; SMALL-MOLECULE INHIBITORS; BREAST-CANCER; RATIONAL DESIGN; RHO GTPASES; CYCLIN D1; TRASTUZUMAB RESISTANCE; TAMOXIFEN RESISTANCE;

D O I：

10.1016/j.critrevonc.2018.01.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rac1 GTPase signaling pathway has a critical role in the regulation of a plethora of cellular functions governing cancer cell behavior. Recently, it has been shown a critical role of Rac1 in the emergence of resistance mechanisms to cancer therapy. This review describes the current knowledge regarding Rac1 pathway deregulation and its association with chemoresistance, radioresistance, resistance to targeted therapies and immune evasion. This supports the idea that interfering Rac1 signaling pathway could be an interesting approach to tackle cancer resistance.

引用

页码：29 / 36

页数：8

共 109 条

[1] VAV3 mediates resistance to breast cancer endocrine therapy [J].

Aguilar, Helena ;

Urruticoechea, Ander ;

Halonen, Pasi ;

Kiyotani, Kazuma ;

Mushiroda, Taisei ;

Barril, Xavier ;

Serra-Musach, Jordi ;

Islam, Abul ;

Caizzi, Livia ;

Di Croce, Luciano ;

Nevedomskaya, Ekaterina ;

Zwart, Wilbert ;

Bostner, Josefine ;

Karlsson, Elin ;

Tenorio, Gizeh Perez ;

Fornander, Tommy ;

Sgroi, Dennis C. ;

Garcia-Mata, Rafael ;

Jansen, Maurice P. H. M. ;

Garcia, Nadia ;

Bonifaci, Nuria ;

Climent, Fina ;

Teresa Soler, Maria ;

Rodriguez-Vida, Alejo ;

Gil, Miguel ;

Brunet, Joan ;

Martrat, Griselda ;

Gomez-Baldo, Laia ;

Extremera, Ana I. ;

Figueras, Agnes ;

Balart, Josep ;

Clarke, Robert ;

Burnstein, Kerry L. ;

Carlson, Kathryn E. ;

Katzenellenbogen, John A. ;

Vizoso, Miguel ;

Esteller, Manel ;

Villanueva, Alberto ;

Rodriguez-Pena, Ana B. ;

Bustelo, Xose R. ;

Nakamura, Yusuke ;

Zembutsu, Hitoshi ;

Stal, Olle ;

Beijersbergen, Roderick L. ;

Angel Pujana, Miguel .

BREAST CANCER RESEARCH, 2014, 16 (03)

[2] SDF-1 synergistically enhances IL-3-induced activation of the Raf-1/MEK/Erk signaling pathway through activation of Rac and its effector Pak kinases to promote hematopoiesis and chemotaxis [J].

Arai, A ;

Jin, A ;

Yan, WH ;

Mizuchi, D ;

Yamamoto, K ;

Nanki, T ;

Miura, O .

CELLULAR SIGNALLING, 2005, 17 (04) :497-506

[3]

Arnold Christoph R, 2014, Oncoscience, V1, P513

[4] P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells [J].

Babagana, Mahamat ;

Johnson, Sydney ;

Slabodkin, Hannah ;

Bshara, Wiam ;

Morrison, Carl ;

Kandel, Eugene S. .

MOLECULAR CARCINOGENESIS, 2017, 56 (05) :1515-1525

[5] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].

Bachelot, Thomas ;

Bourgier, Celine ;

Cropet, Claire ;

Ray-Coquard, Isabelle ;

Ferrero, Jean-Marc ;

Freyer, Gilles ;

Abadie-Lacourtoisie, Sophie ;

Eymard, Jean-Christophe ;

Debled, Marc ;

Spaeth, Dominique ;

Legouffe, Eric ;

Allouache, Djelila ;

El Kouri, Claude ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724

[6] Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells [J].

Balasenthil, S ;

Barnes, CJ ;

Rayala, SK ;

Kumar, R .

FEBS LETTERS, 2004, 567 (2-3) :243-247

[7] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[8]

Beaver JA, 2012, FUTURE ONCOL, V8, P651, DOI [10.2217/fon.12.49, 10.2217/FON.12.49]

[9] RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis [J].

Bid, Hemant K. ;

Roberts, Ryan D. ;

Manchanda, Parmeet K. ;

Houghton, Peter J. .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (10) :1925-1934

[10] Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay [J].

Blangy, Anne ;

Bouquier, Nathalie ;

Gauthier-Rouviere, Cecile ;

Schmidt, Susanne ;

Debant, Anne ;

Leonetti, Jean-Paul ;

Fort, Philippe .

BIOLOGY OF THE CELL, 2006, 98 (09) :511-522

← 1 2 3 4 5 6 7 8 9 10 →